About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is developing a pipeline of small molecule product candidates that are designed to target the sigma-2 receptor (S2R) complex, a regulator of the cellular damage response for diseases, such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA) and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.